Gleaning relapse risk from B cell phenotype: Decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis

Annals of the Rheumatic Diseases

Volumn 74, Issue 9, 2015, Pages 1784-1786

  Bunch, Donna O ^a   Mendoza, Carmen E ^a   Aybar, Lydia T ^a   Kotzen, Elizabeth S ^a   Colby, Kerry R ^a   Hu, Yichun ^a   Hogan, Susan L ^a   Poulton, Caroline J ^a   Schmitz, John L ^a   Falk, Ronald J ^a   Nachman, Patrick H ^a   Pendergraft, William F ^a   McGregor, Julieanne G ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD5 ANTIGEN; RITUXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ANCA ASSOCIATED VASCULITIS; B LYMPHOCYTE; B LYMPHOCYTE DEPLETION; CD5+ B LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; PATIENT MONITORING; PHENOTYPE; PRIORITY JOURNAL; RELAPSE; RESPIRATORY TRACT DISEASE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT; ADULT; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; FEMALE; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PROGNOSIS; RECURRENT DISEASE; REMISSION; RISK ASSESSMENT;

ADULT; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD5; ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RISK ASSESSMENT; RITUXIMAB;

EID: 84939602275     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206756     Document Type: Letter

References (10)

1. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.
2. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.
3. Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013;369:417-27.
4. Pendergraft WF III, Cortazar FB, Wenger J, et al. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol 2014;9:736-44.
5. Calich AL, Puéchal X, Pugnet G, et al., French Vasculitis Study Group. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients. J Autoimmun 2014;50:135-41.
6. Miloslavsky EM, Specks U, Merkel PA, et al. Rituximab for the treatment of relapses in ANCA-associated vasculitis. Arthritis Rheumatol 2014;66:3151-9.
7. + B cells in active Anti-neutrophil Cytoplasmic Autoantibody (ANCA) vasculitis and relapse after rituximab. Clin J Am Soc Nephrol 2013;8:382-91.
8. + regulatory B cells in active anti-neutrophil cytoplasmic autoantibody associated vasculitis permit increased circulating autoantibodies. Clin Exp Immunol 2015;180:178-88.
9. Gary-Gouy H, Harriague J, Bismuth G, et al. Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood 2002;100:4537-43.
10. Schnizlein-Bick CT, Mandy FF, O'Gorman MR, et al. Use of CD45 gating in three and four-color flow cytometric immunophenotyping: guideline from the National Institute of Allergy and Infectious Diseases, Division of AIDS. Cytometry 2002;50:46-52.